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Here we synthesized carbosilane, generation 1 to 3, and PEG-based dendrons functionalized at the 
periphery with NHBoc groups and at the focal point with azide and alkyne moieties, respectively. The 
coupling of these two types of dendrons via click chemistry led to the formation of new hybrid dendrimers 
with two distinct moieties, the hydrophobic carbosilane and the hydrophilic PEG-based dendron. The 
protected dendrimers were transformed into cationic ammonium dendrimers. These unique amphiphilic 
dendrimers were studied as vectors for gene therapy against HIV in peripheral blood mononuclear cells 
(PBMC) and their performance was compared with that of a PEG-free carbosilane dendrimer. The 
presence of the PEG moiety afforded lower toxicities and evidenced a weaker interaction between 
dendrimers and siRNA when compared to the homodendrimer analog. Both features, lower toxicity and 




In recent years, interest in treating diseases by gene therapy has grown as consequence of increased 
knowledge about the molecular pathways of diseases and the human genome. Gene therapy involves 
guiding functional genetic material, such as plasmids, nucleic acids (DNA and RNA) and 
oligonucleotides, to target cells.1 Two types of gene delivery vectors can be distinguished, namely viral 
and non-viral. As a result of the intrinsic nature of viruses, the former have proved to be highly efficient, 
although they also show considerable disadvantages.2,3 The second type are based on synthetic vectors, 
such as macromolecules, polymers and nanosystems, which can be rationally designed according to 
needs.4-11 These vectors are required to interact with nucleic acids, usually forming electrostatic 
complexes, compacting them and preventing their degradation. Thus, various systems functionalized with 
cationic groups have been used for this purpose.12 
In the particular case of dendritic macromolecules, their characteristics, such as a well-defined size and 
structure, flexibility, monodispersity and multivalent molecular surface13-22, have attracted attention for 
biomedical applications. In this regard, several types of cationic dendrimers containing different skeletons 
have been explored for gene therapy.6,10,23-31 One such type comprises carbosilane dendrimers. Although 
these molecules are highly hydrophobic, water-soluble cationic carbosilane dendrimers have proved useful 
as non-viral vectors for gene therapy.32-36 Their strong amphiphilic behavior differentiates them from other 
kinds of dendrimers with a more hydrophilic skeleton. These molecules are able to bind oligonucleotides 
and siRNA and transport them to the interior of a range of cell types.32-36 In addition, these dendrimers 
protect nucleic material from degradation by serum proteins and nucleases. This protective feature is of 
fundamental importance as it ensures that nucleic material can exert an effect once inside the cell.34 
However, the major drawback of cationic dendrimers is their intrinsic toxicity. A strategy developed 
elsewhere to overcome this problem has been the binding of PEG moieties, an approach that also increases 
the solubility of the macromolecule.37-44 
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Taking these previous results into account, here we report the design and synthesis of Janus-type 
amphiphilic dendrimers composed of two types of dendrons, one based on the carbosilane moiety and the 
other on a PEG scaffold, both decorated with ammonium groups at their periphery. The synthesis of these 
dendrimers was performed by click chemistry (CuCAAC) using azide and alkyne groups at the focal point 
of carbosilane and PEG-based dendrons, respectively. Due to this composition, it is expected that these 
dendrimers increase their biocompatibility compared to carbosilane homodendrimers. This feature, along 
with complex formation with siRNA, cellular uptake, and HIV inhibition, was studied in primary 
peripheral blood mononuclear cells (PBMC).  
 
2. Results and Discussion 
2.1. Synthesis of dendrons and Janus-type dendrimers. For the synthesis of carbosilane dendrons, as 
precursors we chose dendrons with a C-Br bond at the focal point and Si-H groups at the periphery.45 We 
have previously reported the synthesis of carbosilane homodendrimers functionalized with amine -NH2 
groups at the periphery by hydrosilylation of allylamine with SiH-terminated dendrimers.35,45 However, 
due to the chemical incompatibility of primary amine groups and C-Br bonds, this procedure is not 
adequate to obtain the dendrons required for preparation of the Janus-type dendrimers objective of this 
study. Therefore protection of the amine groups with Boc was necessary in order to use the same synthetic 
procedure. Thus, the reaction of Boc-protected allylamine C3H5NHBoc with 1-3 generation dendrons 
BrGn(SiH)m (n = 1, m = 2; n = 2, m = 4; n = 3, m =8) (Scheme 1) afforded the corresponding dendrons 
BrGn(NHBoc)m (n = 1, m = 2 (1); n = 2, m = 4 (2); n = 3, m =8 (3)) in moderate yields (ca. 65 %). The 
reaction was followed by NMR spectroscopy, which showed the disappearance of the doublet 
corresponding to the methyl groups and the multiplet of the hydrogen atom of SiMe2H moieties. NMR 
spectroscopy also confirmed formation of these compouds (Figures S3-S4 in supporting information). The 
new chain -Si(CH2)3NH- introduced in  dendrons 1-3 was clearly identified by 
1H-1H TOCSY NMR 
spectra, which showed four resonances at about δ 4.55, 3.05, 1.25 and 0.45. 13C NMR spectra presented 
one resonance at δ ca. 44.0 for the C-N atom of this chain and finally 29Si NMR spectroscopy showed one 
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resonance for the new outer SiMe2 group δ ca. 2.0. The bromine atom at the focal point of compounds 1-3 
was easily replaced by an azide function through the reaction with NaN3 (Scheme 1), thus obtaining the 
dendrons N3Gn(NHBoc)m (n = 1, m = 2 (4); n = 2, m = 4 (5); n = 3, m =8 (6)) in high yield (ca. 85 %). The 
introduction of this group was confirmed by NMR spectroscopy (Figures S5-S8 in supporting 
information), which showed one resonance at δ ca. 3.25 in the 1H NMR spectra and other resonance at δ 


























SiMe(C3H6SiMe(C3H6SiMe2C3H6NHBoc)2)2 (6)  
Scheme 1. Synthesis of generation 1-3 carbosilane dendrons N3Gn(NHBoc)m (n = 1, m = 2 (4); n = 2, m 
= 4 (5); n = 3, m =8 (6)). i) C3H5NHBoc, Pt Kardstedt’s catalyst, THF, 60 ºC, 12 h; ii) NaN3, DMF, NaI, 




The alkyne PEG-based dendron consisted of a branching unit derived from 
diethylenetriaminepentaacetic acid (DTPA), to which PEG-chains of exact molecular weight (1-(tert-
butoxycarbonyl-amino)-4,7,10-trioxa-13-tridecanamine) were incorporated. The DTPA derivative 
contains an alkyne moiety at its focal point instead of a carboxylic one, and was synthesized as follows 
(Scheme 2). Initially, tert-butyl bromoacetate was reacted with ethanolamine, after which HO/Br exchange 
using N-bromosuccinimide (NBS) and PPh3 afforded compound 7 in good yield (71 %), as confirmed by 
HPLC-MS and NMR  (Figures S9-S10 in supporting information). The main NMR data for this 
compound in the 1H NMR spectrum are the singlet at δ 3.48 for the CH2CO group and the triplets at δ 
3.13 and 3.48 for the -N(CH2)2Br chain. The alkyne DTPA derivative 8 was then obtained by coupling 
two units of 7 to propargylamine (83 % yield). This resulted to be the key step in the synthesis of the final 
dendron because we were able to minimize the overalkylation of the propargylamine. The best results 
were achieved using DIEA as base (2 equiv.) and heating at 80 °C. The presence of the propargylamino 
fragment gave rise to a shifting to lower frequency of the N(CH2)2N chain to δ 2.66 and 2.84 in the 
1H 
NMR spectrum  (Figures S11-S12 in supporting information). 
Afterwards, the tert-butyl groups were removed under acidic conditions and the PEG-chains were 
introduced by amide bond formation, rendering the desired dendron 10 in satisfactory yield (84 %), which 
was characterized by NMR  (Figures S13-S14 in supporting information), HPLC-MS and HR-MS. In this 
compound, the presence of the new amide groups were distinguished in 1H NMR spectroscopy by means 
of one broad resonance at δ 7.51 for the NH protons, whereas the NH protons of the NHBoc groups were 





Scheme 2. Synthesis of 10. i) KHCO3, DMF, r. t., 22 h; ii) NBS, PPh3, CH2Cl2, 0ºC, 2 h; iii) NH2C3H3, 
DIPEA, CH3CN, 24 h, 80ºC; iv) HCl/dioxane, 16 h, r. t.; v) Boc-1-amino-4,7,10-trioxa-13-tridecanamine, 
CH2Cl2:DMF (7:3, v:v), solid PyBOP, DIPEA (pH = 8), 1 h, r. t. 
 
The coupling of azide carbosilane dendrons N3Gn(NHBoc)m (4-6) with alkyne PEG-based wedge 10 was 
carried out in THF/H2O in the presence of Cu
+ at 60 ºC (Scheme 3), leading to the hybrid dendrimers 11-
13. The yield of this reaction was dependent on the generation of carbosilane dendron. While compounds 
11 and 12 were obtained in acceptable yield (ca. 80 %), compound 13 was isolated in very low yield (23 
%). The formation of amphiphilic dendrimers was confirmed by NMR spectroscopy  (Figures S15-S18 in 
supporting information). The 1H NMR spectra showed one resonance at about δ 7.50 for the CH proton of 
the triazole ring and the 13C NMR spectra showed resonances at about δ 122 and δ 144 for the CH and i-C 
carbons of this ring, respectively. With respect to the two CH2 groups bound to the triazole ring, the one 
stemming from the carbosilane dendron was observed about δ 4.30 in 1H NMR spectroscopy and at about 
δ 50.0 in 13C NMR spectroscopy, whereas the one derived from the PEG-based dendron was observed at 




Scheme 3. Synthesis of amphiphilic cationic dendrimers from carbosilane dendrons N3Gn(NHBoc)m (4-
6) and PEG-based dendron 10. i) CuSO4, NaAsc, NEt3, THF/H2O (6:2 v:v), 16 h, 60ºC; ii) HCl/dioxane, 5 
h, r. t. 
 
Treatment of NHBoc dendrimers 11-13 with excess HCl in dioxane led to the corresponding 
amphiphilic cationic dendrimers 14-16 (Scheme 3, Figure 1), which were isolated as white powders that 
were soluble in H2O, in contrast to the starting compounds. The main NMR data (Figures S19-S22 in 
supporting information) of these compounds are, on the one hand, the disappearance of the tBu resonances 
of Boc groups and, on the other hand, the resonances for the NH3
+ protons observed in the 1H NMR 
spectra about δ 8.00 (DMSO-d6). In addition, in Figure 1, the analog carbosilane homodendrimer of 









































































Figure 1. Drawing of cationic amphiphilic dendrimers 14-16 described in this study and generation two 




3. Biomedical assays 
The potential application of amphiphilic dendrimers 14 and 15 for gene therapy, with 6 and 8 
ammonium NH3
+ groups respectively, was studied against HIV in PBMC and compared with that of the 
carbosilane homodendrimer 1735 with 8 NH3
+ groups (Figure 1). The very low yield obtained in the 
synthesis of the amphiphilic dendrimer 16 precluded its use in these studies. 
First, we tested the toxicity of these dendrimers by MTT assays to measure mitochondrial metabolic 
activity (Figure 2A). Compounds 14 and 15 were non-toxic up to 5 and 10 μM respectively, whereas 
carbosilane dendrimer 17 showed toxicity over 1 μM. Although it is clear that the presence of PEG 
fragments diminished the toxicity, the carbosilane moiety also might play a role, as the toxicity of 14 was 









Figure 2. Cytotoxicity (MTT) of dendrimers 14, 15 and 17 (A) and the corresponding dendriplexes (B) 
at variable siRNA Nef:dendrimer charge ratios (−/+) in PBMC with siRNA Nef concentration of 25 nM. 
Dextrane (5M) and DMSO (15%) were used as positive and negative controls respectively. 
 
Also, the toxicity of dendriplexes was evaluated by MTT (Figure 2B). These experiments showed again 
higher tolerance for dendriplexes formed by Janus-type dendrimers 14 and 15 than for carbosilane 
homodendrimer 17. Dendriplexes formed by dendrimer 14 were biocompatible up to a siRNA:dendrimer 




were non-toxic only below a ratio of 1:2 (−/+). These results are in agreement with the toxicity observed 
for dendrimers alone. 
Electrophoresis analyses in agarose gel were performed to study the binding capacity of these 
dendrimers toward siRNA Nef (Figure 3). Amphiphilic dendrimer 14 formed a complex with siRNA Nef 
from a ratio of 1:4 (−/+) at 2 h but released it after 24 h, being stable over time at a higher ratio. However, 
dendritic systems with 8 NH3
+ groups, 15 and 17, formed more stable complexes in which the cargo was 
not released after 24 h. For amphiphilic dendrimer 15, the dendriplex was formed from ratios 1:8 (−/+) but 
for carbosilane homodendrimer 17 stable dendriplexes were generated from ratios 1:1 (−/+). In any case, 




Figure 3. Electrophoresis gel in agarose of dendriplexes at different siRNA Nef:dendrimer charge ratios 








Figure 4. Polyacrylamide gel electrophoresis of dendriplexes/heparin competition assays after 24 h. The 
y –axis denotes free siRNA while concentration of heparin was measured in International Units of 
heparine per μg of siRNA (U/μg). 
 
In order to test the strength of the interaction between siRNA and dendrimers, heparin competition 
assays were performed (Figure 4). The −/+ charge ratio of dendriplexes that has been used for this 
experiment corresponds with the best results found in the biocompatibility assays, 1:4 for compound 14, 
1:8 dendriplex for compound 15 and 1:2 dendriplex for compound 17. Polyacrylamide gel electrophoresis 
(PAGE) was used to adequately visualize and quantify the siRNA released from the dendriplex as heparin 
concentration increased. It was found that such release process began at 0.1 U/µg for the three types of 
dendriplexes. However, the influence of PEG units was clear again, as higher retention was shown by free-
PEG dendrimer 17. Analogous dendritic systems to the homodendrimers 17 containing –CH2NMe3
+ at the 
periphery resulted to be inactive regarding HIV inhibition when dendriplexes were used.46 This drawback 
was ascribed to the high stability shown by the dendriplexes, which enabled them to internalize their cargo 
but prevented their release inside the cell for in vitro experiments. The presence of PEG moieties 
weakened these interactions, which could be a key feature in transfection processes. 
Because of the charge ratio is different for every dendrimer used, it seems difficult to compare among 
them in term of relative strength. However, it is also plausible that the difficulty on releasing the siRNA 
may increase on increasing the charge ratio at least until certain limits. Therefore, if a 1:4 charge ratio 
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(−/+) were used for dendrimers 15 instead of 1:8, higher liberation of siRNA may be observed while the 
opposite would be true if dendrimer 17 were tested at such ratio, supporting again the assumption of the 
influence of PEG units on the biological properties of the Janus dendrimers. 
Zeta-potential and size measurement experiments have been carried out for dendriplexes formed by 
dendrimers 14, 15 or 17 and siRNA-Nef (see Supporting Information). The differences between the charge 
ratio profiles of dendriplexes measured by Z-potential corroborate the intensity of interactions between de 
different dendrimers and siRNA. The lower zeta-potential values observed for 14 and 15 respecting 17 
dendriplexes with siRNA show more efficiency in term of transfection and biocompatibility. Although, a 
positive charge on surface dendriplex facilitates cell absortion and mediates efficient endosomal uptake, 
high positive charges imply cytotoxicity and non-specific binding to others biological components. 
However, respecting particle size, no rational data were obtained for comparing among different 
dendriplexes. 
Finally, a post-treatment inhibitory study on PBMC by p24 ELISA assay was done to determine the 
capacity of dendrimer/siRNA Nef dendriplexes to interfere in HIV replication (Figure 5). The efficiency of 
siRNA delivery is close related to the formation of p24 antigen. The siNef inhibit the formation of the 
viral Nef protein which is vital for the formation of new viral particles represented by the detection of the 
p24 antigen. The p24 protein is present in the HIV core; therefore quantification of this antigen is a 
method to evaluate the inhibition ability of any system once the cells are infected. Of the three systems 
used, the one formed with Janus-type dendrimer 15 gave the best results, showing inhibition of up to 50 
%. This result marks a clear difference with respect to those obtained for the dendriplexes formed with 
Janus-type dendrimer 14 and homodendrimer 17. Thus, siRNA delivery is more favorable in the case of 
dendriplex formed with 15, an observation that corroborates the electrophoregrams described previously, 
although release of siRNA from 15 is less than from 14 (see Fig. 3 and 4), whereas the retention strength 
of dendrimer 17 with respect to the siRNA probably is the major drawback of this system. It is likely that 
the complex of siRNA with compound 15 has a unique structure, and/or larger excess dendritic 
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compounds might affect the efficient siRNA delivery. Finally, dendriplex of 15 showed an activity similar 
to that of the dendriplex formed with the well-known PEI system (at −/+ charge ratio 1:2), XXX 
 
Figure 5. HIV protein p24 ELISA test of infected PBMC after 48 h of treatment. AZT denotes 
zidovudine (replication inhibitor); T20 is enfuvirtide (fusion inhibitor); 14, 15 and 17 mean inhibition in 
the presence of dendrimers alone below their cytotoxicity levels, 5, 10 and 1 μM respectively; 14 1/4, 15 
1/8 and 17 1/2 mean dendriplexes of the corresponding dendrimers at those −/+ charge ratio. Dendriplexes 
with random siRNA were formed at the same charge ratio than siRNA Nef. siRNA concentrations of 250 
nM were used. Incubation time for dendriplex formation was 15 minutes and incubation time of PBMC 
with HIV virus was 1 h. 
 
4. Conclusions 
The click coupling of azide carbosilane dendrons (generations 1 and 2) and alkyne PEG-based dendron 
has been successfully used as building blocks to synthesize Janus-type cationic dendrimers functionalized 
with 6 and 8 ammonium NH3
+ groups. However, for higher generations this reaction was not successful, 
as very low yield was obtained when the corresponding carbosilane dendron of generation 3 was used. The 
performance of heterodendrimers 14 and 15 was compared with a carbosilane homodendrimer with 8 
NH3
+ groups (17) as gene delivery vectors against HIV in PBMC. The presence of the PEG moiety 
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afforded lower toxicities than the homodendrimer analog, and the same trend was observed when the 
corresponding dendriplexes were used. With respect to dendriplex strength, electrophoresis analyses 
showed that dendrimers 14 and 15 formed dendriplexes at higher ratios than the homodendrimer 17, thus 
evidencing a weaker interaction between dendrimers and siRNA. This finding was corroborated by the 
dendriplex/heparin competition assays. Both lower toxicity and lower dendriplex strength, ascribed to the 
presence of PEG moieties, could be crucial properties for their use as carriers of nucleic material, as 
Janus-type dendrimer 15 showed greater HIV inhibitory activity than homodendrimer 17 containing the 
same number of positive charges. 
 
4. Experimental Section 
4.1. General Considerations. All reactions were carried out under inert atmosphere and solvents were 
purified from appropriate drying agents when necessary (THF). NMR spectra were recorded on a Varian 
Unity VXR-300 (300.13 (1H), 75.47 (13C) MHz) or on a Bruker AV400 (400.13 (1H), 100.60 (13C), 79.49 
(29Si) MHz). Chemical shifts (δ) are given in ppm. 1H and 13C resonances were measured relative to 
solvent peaks, considering TMS = 0 ppm. 29Si resonances were measured relative to external TMS. When 
necessary, assignment of resonances was done from HSQC, HMBC, COSY, TOCSY and NOESY NMR 
experiments. Elemental analyses were performed on a Perkin-Elmer 240C. Mass spectra were obtained 
from an Agilent 6210 (ESI), a Bruker Ultraflex III (MALDI-TOF) and a Thermo Scientific LTQ-FT Ultra 
(HRMS). Analytical HPLC was carried out on a Waters (Ireland) instrument comprising a Sunfire™ C18 
reversed-phase analytical column, 3.5 μm, 4.6 x 100 mm, a separation module (Waters 2695), automatic 
injector, and photodiode array detector (Waters 2298). HPLC-MS analyses of peptide samples were 
carried out on a Waters (Ireland) instrument comprising a Sunfire™ C18 reversed-phase analytical 
column, 3.5 μm, 4.6 x 100 mm, a separation module (Waters 2695), automatic injector, photodiode array 
detector (Waters 2298), and a Waters micromass ZQ unit. The zeta potential measurements were carried 
out with a Malvern NanoZS instrument. Compounds Karstedt’s Pt catalyst, C3H5NHBoc, NaN3, 
NaAscorbate, tert-butyl bromoacetate, PPh3, NBS, propargylamine (Aldrich), 1-(tert-butyloxycarbonyl-
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amino)-4,7,10-trioxa-13-tridecanamine (Iris Biotech) and CuSO4 (Panreac) were obtained from 
commercial sources. Compounds BrGn(SiH)m (n = 1, m = 2; n = 2, m = 4; n = 3, m =8)
45 and cationic 
carbosilane dendrimer 1735 were synthesized as published. 
 
4.2. Synthesis of compounds. 
NMR data of dendrimers and dendrons of first generation and compounds 7-10 are labeled with letters. 
The corresponding labeled NMR spectra and structures are collected in supporting information. 
Synthesis of BrG1Boc2 (1). A solution of BrG1(SiH)2 (2.00 g, 5.24 mmol) and C5H3NHBoc (1.71 g, 
10.90 mmol) in THF (5 mL) was stirred at 40 ºC for 8 h in a teflon-valved ampoule in the presence of 
platinum Karstedt’s catalyst. Afterwards the solvent was removed under vacuum, and 1 was purified by 
column chromatography (hexane:THF 5:2), which gave 1 as a colorless oil (2.88 g, 79 %). NMR data 
(CDCl3): 
1H NMR: -0.09 (s, 3 H, SiMe (e)), -0.07 (s, 12 H, SiMe2 (i)), 0.43 (m, 6 H, CH2Si (j)), 0.52 (m, 8 
H, CH2Si (f, h)), 1.23 (m, 6 H, CH2CH2CH2 (c, g)), 1.42 (s, 22 H, SiCH2CH2CH2N and tBu (k, n)), 1.78 
(m, 2 H, BrCH2CH2CH2CH2 (b)), 3.06 (m, 4 H, CH2NH (l)), 3.40 (t, J = 6.80 Hz, 2 H, BrCH2 (a)), 4.54 (s, 
2 H, NH (m)). 13C NMR: -5.1 (SiMe), -3.4 (SiMe2), 12.4 (SiCH2CH2CH2N), 13.0 (SiCH2), 18.4, 18.6, 
20.0 (SiCH2 and SiCH2CH2), 22.4 (BrCH2CH2CH2CH2), 22.6 (BrCH2CH2CH2CH2), 24.6 
(SiCH2CH2CH2NH), 28.4 (CMe3), 33.7 (BrCH2CH2CH2CH2), 36.3 (BrCH2CH2CH2CH2), 43.8 (CH2N), 
79.9 (CMe3), 155.9 (NHCOO). 
29Si NMR: 1.8 (SiMe), 2.0 (SiMe2). MS (MALDITOF): 695.3656 [M + 
H+]. Anal. Calc. for C31H67BrN2O4Si3 (696.04): C, 53.46; H, 7.90; N, 4.02; Obt.: C, 53.32; H, 7.79; N, 
3.94. 
Synthesis of BrG2Boc4 (2). Following the procedure described above for 1, from BrG2(SiH)4 (1.50 g, 
1.99 mmol) and C5H3NHBoc (1.31 g, 8.35 mmol) in THF (3 mL) afforded 2 as a colorless oil (1.68 g, 61 
%). NMR data (CDCl3): 
1H NMR: -0.12 (s, 6 H, SiMe), -0.09 (s, 3 H, SiMe), -0.07 (s, 24 H, SiMe2), 0.42 
(m, 10 H, CH2Si), 0.52 (m, 24 H, CH2Si), 1.23 (m, 14 H, CH2CH2CH2), 1.42 (s, 44 H, SiCH2CH2CH2N 
and tBu), 1.78 (m, 2 H, BrCH2CH2CH2CH2), 3.05 (m, 8 H, CH2NH), 3.39 (t, J = 6.80 Hz, 2 H, BrCH2), 
4.57 (s, 4 H, NH). 13C NMR: -5.1 (SiMe), -5.0 (SiMe), -3.4 (SiMe2), 12.4 (SiCH2CH2CH2N), 13.0 
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(SiCH2), 18.4, 18.8, 18.9, 20.0 (SiCH2 and SiCH2CH2), 22.5 (BrCH2CH2CH2CH2 and 
BrCH2CH2CH2CH2), 24.6 (SiCH2CH2CH2NH), 28.4 (CMe3), 33.6 (BrCH2CH2CH2CH2), 36.4 
(BrCH2CH2CH2CH2), 43.8 (CH2N), 79.0 (CMe3), 155.9 (NHCOO). 
29Si NMR: 1.7 (SiMe), 2.1 (SiMe2). 
MS (MALDITOF): 1381.8389 [M + H+]. Anal. Calc. for C65H141BrN4O8Si7 (1383.34): C, 56.44; H, 10.27; 
N, 4.05; Obt.: C, 56.26; H, 10.49; N, 4.27. 
Synthesis of BrG3Boc8 (3). Following the procedure described above for 1, from BrG3(SiH)8 (1.10 g, 
0.73 mmol) and C5H3NHBoc (0.97 g, 6.16 mmol) afforded 3 as a colorless oil (1.27 g, 63 %) after size 
exclusion chromatography with THF. NMR data (CDCl3): 
1H NMR: -0.11 (s, 21 H, SiMe), -0.07 (s, 48 H, 
SiMe2), 0.43 (m, 18 H, CH2Si), 0.52 (m, 56 H, CH2Si), 1.23 (m, 30 H, CH2CH2CH2), 1.42 (s, 88 H, 
SiCH2CH2CH2N and tBu), 1.78 (m, 2 H, BrCH2CH2CH2CH2), 3.04 (m, 16 H, CH2NH), 3.39 (t, J = 6.80 
Hz, 2 H, BrCH2), 4.58 (s, 4 H, NH). 
13C NMR: -4.9 (SiMe), -3.4 (SiMe2), 12.4 (SiCH2CH2CH2N), 13.6 
(SiCH2), 18.4, 18.5, 18.8, 19.0, 20.0 (SiCH2 and SiCH2CH2), 22.5 (BrCH2CH2CH2CH2 and 
BrCH2CH2CH2CH2), 24.6 (SiCH2CH2CH2NH), 28.4 (CMe3), 33.6 (BrCH2CH2CH2CH2), 36.4 
(BrCH2CH2CH2CH2), 43.8 (CH2N), 78.9 (CMe3), 156.0 (NHCOO). 
29Si NMR: 1.7 (SiMe), 2.1 (SiMe2). 
Anal. Calc. for C133H289BrN8O16Si15 (2757.95): C, 57.92; H, 10.96; N, 4.06; Obt.: C, 57.81; H, 10.49; N, 
3.88. 
Synthesis of N3G1Boc2 (4). A solution of 1 (1.50 g, 2.16 mmol) and NaN3 (0.56 g, 8.62 mmol) in 
DMF (20 mL) was stirred at 80 ºC for 16 h in a teflon-valved ampoule. Afterwards the solvent was 
removed under vacuum and extraction with Et2O and brine was carried out. The organic phase was dried 
with MgSO4 and filtered, and the solvent was removed under vacuum to give 4 as a colorless oil (1.28 g, 
87 %). NMR data (CDCl3): 
1H NMR: -0.09 (s, 3 H, SiMe (e)), -0.07 (s, 12 H, SiMe2 (i)), 0.43 (m, 6 H, 
CH2Si (d, j)), 0.51 (m, 8 H, CH2Si (f, h)), 1.27 (m, 6 H, CH2CH2CH2 (c, g)), 1.42 (s, 22 H, 
SiCH2CH2CH2N (k) and tBu (p)), 1.60 (m, 2 H, N3CH2CH2 (b)), 3.05 (m, 4 H, CH2NH (l)), 3.25 (t, J = 
6.8 Hz, 2 H, N3CH2 (a)), 4.54 (s, 2 H, NH (m)). 
13C NMR: -5.1 (SiMe), -3.4 (SiMe2), 12.4 
(SiCH2CH2CH2N), 13.6 (SiCH2), 18.4, 18.6, 20.0 (SiCH2) and SiCH2CH2), 21.2 (N3CH2CH2CH2CH2), 
24.6 (SiCH2CH2CH2NH), 28.4 (CMe3), 32.7 (N3CH2CH2), 43.8 (CH2N), 51.1 (N3CH2), 79.0 (CMe3), 
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155.9 (NHCOO). 29Si NMR: 1.7 (SiMe), 2.0 (SiMe2). MS (MALDITOF): 658.4531 [M + H]
+. Anal. Calc. 
for C31H67N5O4Si3 (658.15): C, 56.57; H, 10.26; N, 10.64; Obt.: C, 56.42; H, 10.13; N, 10.21. 
Synthesis of N3G2Boc4 (5). Following the procedure described above for 4, from 2 (1.22 g, 0.88 
mmol) and NaN3 (0.23 g, 3.53 mmol) afforded 5 as a colorless oil (1.03 g, 87 %). NMR data (CDCl3): 
1H 
NMR: -0.09 (s, 3 H, SiMe), -0.09 (s, 6 H, SiMe), -0.07 (s, 24 H, SiMe2), 0.43 (m, 10 H, CH2Si), 0.51 (m, 
24 H, CH2Si), 1.27 (m, 14 H, CH2CH2CH2), 1.42 (s, 44 H, SiCH2CH2CH2N and tBu), 1.60 (m, 2 H, 
N3CH2CH2), 3.05 (m, 8 H, CH2NH), 3.25 (t, J = 6.8 Hz, 2 H, N3CH2), 4.54 (s, 4 H, NH). 
13C NMR: -5.1 
(SiMe), -5.0 (SiMe), -3.4 (SiMe2), 12.4 (SiCH2CH2CH2N), 13.5 (SiCH2), 18.4, 18.5, 18.8, 18.9, 20.0 
(SiCH2 and SiCH2CH2), 21.2 (N3CH2CH2CH2CH2), 24.6 (SiCH2CH2CH2NH), 28.4 (CMe3), 32.6 
(N3CH2CH2), 43.8 (CH2N), 51.1 (N3CH2), 78.9 (CMe3), 155.9 (NHCOO). 
29Si NMR: 1.7 (SiMe), 2.0 
(SiMe2). MS (MALDITOF): 1344.9293 [M + H]
+. Anal. Calc. for C65H141N7O8Si7 (1345.46): C, 58.02; H, 
10.56; N, 7.29; Obt.: C, 58.21; H, 10.33; N, 7.11. 
Synthesis of N3G3Boc8 (6). Following the procedure described above for 4, from 3 (1.05 g, 0.38 
mmol) and NaN3 (0.062 g, 0.95 mmol) afforded 6 as a white wax (0.82 g, 80 %). NMR data (CDCl3): 
1H 
NMR: -0.11 (s, 21 H, SiMe), -0.07 (s, 48 H, SiMe), 0.43 (m, 18 H, CH2Si), 0.51 (m, 56 H, CH2Si), 1.27 
(m, 30 H, CH2CH2CH2), 1.42 (s, 88 H, SiCH2CH2CH2N) and tBu), 1.60 (m, 2 H, N3CH2CH2), 3.05 (m, 16 
H, CH2NH), 3.25 (t, J = 6.8 Hz, 2 H, N3CH2), 4.59 (bs, 8 H, NH). 
13C NMR: -5.1 and -5.0 (SiMe), -3.4 
(SiMe2), 12.4 (SiCH2CH2CH2N), 13.5 (SiCH2), 18.4, 18.5, 18.8, 18.9, 20.0 (SiCH2) and SiCH2CH2), 21.2 
(N3CH2CH2CH2CH2), 24.6 (SiCH2CH2CH2NH), 28.4 (CMe3), 32.6 (N3CH2CH2), 43.8 (CH2N), 51.1 
(N3CH2), 78.9 (CMe3), 156.0 (NHCOO). 
29Si NMR: 1.7 (SiMe), 2.1 (SiMe2). Anal. Calc. for 
C133H289N11O16Si15 (2720.06): C, 58.73; H, 10.71; N, 5.66; Obt.: C, 58.99; H, 10.87; N, 5.31. 
Synthesis of 2-[Bis-(tert-butyloxycarbonylmethyl)amino]ethyl bromide (7). 
KHCO3 was added (6.18 g, 61.8 mmol, 2.5 eq.) to a solution of tert-butyl bromoacetate (8.05 mL, 54.5 
mmol, 2.2 eq.) in 50 mL of anhydrous DMF. The suspension was cooled at 0 ºC, ethanolamine (1.48 mL, 
24.5 mmol, 1 eq.) was added via a syringe over a 5-min period, and the solution was stirred at 0 ºC for 30 
min. The reaction mixture was then allowed to warm to room temperature and stirred for 22 h. After this 
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time, most of the DMF was evaporated under vacuum and 50 mL of saturated NaHCO3 was added. The 
resulting mixture was extracted with diethyl ether (3×50 mL), and the combined organic phases were 
washed with 50 mL of brine, dried with Na2SO4, and evaporated to afford the crude product N,N-bis[(tert-
butoxycarbonyl)methyl]-2-hydroxyethylamine (7.41 g) as an oil. This crude product was dissolved in 
CH2Cl2 and solid PPh3 (8.66 g, 33.0 mmol, 1.3 eq.) was added to the solution that was cooled at 0 ºC. 
After that, solid NBS (5.87 g, 33.0 mmol, 1.3 eq.) was added over a 5-min period and the mixture was 
stirred for 2 h at 0 ºC. After this time the solvent was evaporated and a semisolid residue was obtained, 
which was then triturated with diethyl ether. The solid was filtered, washed with ether and discarded, and 
the ether phase was evaporated to afford an oily residue, which was purified by flash chromatography on 
silica (530% diethyl ether in hexane) yielding 7 (6.18 g, 71%).  
NMR data of N,N-bis[(tert-butoxycarbonyl)methyl]-2-hydroxyethylamine (CDCl3): 
1H NMR: 1.45 (s, 
18 H, tBu), 2.82 (t, J = 4.89 Hz, 2 H, HOCH2CH2), 3.38 (s, 2 H, NCH2CO), 3.46 (t, J = 4.98 Hz, 4 H, 
HOCH2CH2), and 3.64 (bs, OH); 
13C NMR: 27.9 (CMe3), 56.5 (NCH2CO), 56.9 (HOCH2CH2), 58.2 
(HOCH2CH2), 81.3 (CMe3), 171.2 (NCH2CO). MS: Theoretical mass for C14H27O5N: 289.2; Mass found 
by HPLC-MS: 290.1 (M+1).  
NMR data of 7 (CDCl3): 
1H NMR: 1.46 (s, 18 H, tBu (d)), 3.13 (t, J = 7.82 Hz, 2 H, BrCH2CH2 (b)), 
3.44 (t, J = 7.82 Hz, 2 H, BrCH2CH2 (a)), and 3.48 (s, 4 H, NCH2CO (c)). 
13C NMR: 28.1 (CMe3), 30.2 
(BrCH2CH2), 56.5 (NCH2CO), 56.6 (BrCH2CH2), 81.2 (CMe3), 170.5 (NCH2CO).. MS: Theoretical mass 
for C14H26BrO4N: 351.1; Mass found by HPLC-MS: 352.0 (M+1). 
Synthesis of 4-(Prop-2-ynyl)-1,1,7,7-tetra(tert-butoxycarbonylmethyl)-1,4,7-triazaheptane (8). 
Propargylamine (0.103 mL, 1.61 mmol) and DIEA (1.285 mL, 7.0 mmol) were added to a solution of 
bromoderivative 7 (1.250 g, 3.55 mmol) in 100 mL of acetonitrile,. The resulting mixture was stirred at 80 
ºC for 24 h. Afterwards the acetonitrile was evaporated, and the resulting oil was dissolved in ethyl 
acetate. The organic phase was washed three times with an aqueous solution of 5% NaHCO3, dried over 
MgSO4 and evaporated. The yellow oil obtained was flash chromatographed on basic aluminum oxide 




1.45 (s, 36 H, tBu (f)), 2.15 (t, J = 2.2 Hz, 1 H, NCH2CCH (a)), 2.66 (t, J = 6.9 Hz, 4 H, 
NCH2CH2NCH2CH2N (c)), 2.84 (t, 6.9 Hz, 4 H, NCH2CH2NCH2CH2N (d)), 3.46 (s, 8 H, NCH2CO (e)), 
3.54 (d, J = 2.2 Hz, 2 H, NCH2CCH (b)); 
13C NMR: δ: 28.2 (CMe3), 42.0 (NCH2CCH), 51.7 
(NCH2CH2NCH2CH2N), 52.1 (NCH2CH2NCH2CH2N), 56.1 (NCH2CO), 73.0 (NCH2CCH), 78.7 
(NCH2CCH), 80.8 (CMe3), 170.7 (NCH2CO). MS: Theoretical mass for C31H55N3O8: 597.4. Experimental 
mass detected by LC-MS: 598.0 (M+1). Experimental mass detected by HRMS: 598.4060 (M+1). 
Synthesis of 4-(prop-2-ynyl)-1,1,7,7-tetra(carboxymethyl)-1,4,7-triazaheptane (9). 
Compound 8 (0.400 g, 0.66 mmol) was dissolved in 4.0 M HCl in dioxane (10 mL, 40 mmol) and the 
mixture was stirred overnight at room temperature. HCl and dioxane were then removed by evaporation 
and the resulting crude product was coevaporated with dioxane (× 3), affording compound 9 as the 
corresponding hydrochloride salt (0.360 g), which was used for the next step without further purification. 
Synthesis of alkyne-functionalized PEG dendron 10. 
Solid PyBOP (1.510 g, 2.90 mmol) and 1-(tert-butyloxycarbonyl-amino)-4,7,10-trioxa-13-tridecanamine 
(0.930 g, 2.90 mmol,) dissolved in 10 mL of CH2Cl2 were added to a solution of compound 9 in 500 mL 
of anhydrous CH2Cl2:DMF (7:3, v:v). The pH was adjusted to 8 with DIEA. After 1 h of stirring at room 
temperature, the solvents were removed in vacuo. The resulting crude product was dissolved in 100 mL of 
CH2Cl2 and washed with 5% NaHCO3 (3× 100 mL). The organic phase was evaporated, and the resulting 
crude product dissolved in CH2Cl2 (10 mL) ,was transferred to a 50-mL tube, and then hexane (40 mL) 
was added. The mixture was stirred vigorously and centrifuged. The supernatant was discarded, and the 
remaining oily precipitate corresponded to pure compound 10 (0.877 g, 84 % yield). NMR data (CDCl3): 
1H NMR: δ 1.43 (s, 36 H, tBu (r)), 1.78 (m, 16 H, NHCH2CH2CH2O (h)), 2.26 (t, J = 2.2 Hz, 1 H, 
NCH2CCH (a)), 2.64 (m, 8 H, NCH2CH2NCH2CH2N (c, d)) 3.21 (m, 16 H, NCH2CH2CH2O (g,p)), 3.34 
(m, 8 H, NCH2CO (e)), 3.39 (d, J = 1.6 Hz, 2H, NCH2CCH (b)), 3.53 (m, 16 H, NHCH2CH2CH2O (n, i)), 
3.57-3.66 (m, 32 H, OCH2CH2O (j-m)), 5.10 (bs, NH (q)), 7.51 (bs, NH (f)). 
13C NMR (CDCl3): δ 28.4 
(CMe3), 29.5 (OCONHCH2CH2CH2O), 29.7 (NCH2CONCH2CH2CH2O), 37.1 
(NCH2CONCH2CH2CH2O), 38.4 (OCONHCH2CH2CH2O), 46.2 (NCH2CCH), 51.7 
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(NCH2CH2NCH2CH2N), 53.2 (NCH2CH2NCH2CH2N), 59.0 (NCH2CO), 69.4 (OCONHCH2CH2CH2O), 
69.5 (NCH2CONHCH2CH2CH2O), 70.2 (OCH2CH2O), 73.9 (CMe3), 77.8 (NCH2CCH), 78.9 
(NCH2CCH), 156.0 (OCONHCH2CH2CH2O), 170.7 (NCH2CONCH2CH2CH2O). MS: Theoretical mass 
for C75H143N11O24: 1582.03. Experimental mass detected by LC-MS: 792.64 ((M+2)/2). Experimental 
mass detected by HRMS: 1583.0358 (M+1).  
Synthesis of dendrimer 11. Compounds 4 (0.069 g, 0.104 mmol) and 10 (0.150 g, 0.095 mmol) were 
stirred under argon atmosphere in a mixture of THF/H2O (6/2 ml) at 40ºC in the presence of CuSO4 (7% 
mol), NaAscorbate (15% mol) and NEt3 (20% mol) for 16 h. Afterwards, the reaction was treated with few 
drops of NH4OH (30%) and the product was extracted with AcOEt against a saturated water solution of 
NH4Cl. The organic phase was dried with MgSO4, the solvent was removed under vacuum, and the 
remaining oil was washed with hexane (10 mL) to give compound 11 as yellowish oil (0.176 g, 83 %). 
NMR data (CDCl3): 
1H NMR: -0.07 (s, 15 H, SiMe (e, i)), 0.47 (m, 6 H, CH2Si (d,j)), 0.52 (m, 8 H, CH2Si 
(f, h)), 1.23 (m, 6 H, CH2CH2CH2 (c, g)), 1.41 (m, 58 H, SiCH2CH2CH2N and tBu (k, n, r’)), 1.73 (m, 16 
H, OCH2CH2CH2N (o’)), 1.89 (m, 2 H, N-NCH2CH2 (b)), 2.54 (t, J = 7.3 Hz, 2 H, NCH2CH2N (c’)), 2.68 
(t, J = 7.3 Hz, 2 H, NCH2CH2N (d’)), 3.04 (m, 4 H, CH2NH (l)), 3.16 (m, 16 H, CH2NH and CH2CO), 
3.28 (m, 8 H, CH2NH), 3.45-3.60 (m, 48 H, OCH2 (j’-m’)), 3.70 (s, 2 H, CspCH2N (b’)), 4.31 (t, J = 6.8 
Hz, 2 H, CH2NN (a)), 4.64 (br. s, 2 H, NH (m)), 5.05 (br. s, 4 H, NH (q’)), 7.50 (s, 1 H, CspH (a’)), 7.75 
(br. s, 4 H, NH (f’)). 13C NMR: -5.1 (SiMe), -3.3 (SiMe2), 12.4 (SiCH2CH2CH2N), 13.6 (SiCH2), 18.4, 
18.7, 20.0, 21.2 (SiCH2 and SiCH2CH2), 24.7 (SiCH2CH2CH2NH), 28.5 (CMe3), 29.6 and 29.7 
(NHCH2CH2CH2O), 34.3 (N-NCH2CH2), 37.0 (CH2NH), 38.5 (CH2NH), 43.8 (CH2NH), 46.3 (CspCH2N), 
50.1 (CH2NN), 51.4 (NCH2CH2N), 52.7 (NCH2CH2N), 58.9 (CH2CO), 69.4, 69.5, 70.2, 70.5 (OCH2), 
78.9 (CMe3), 122.7 (CH=C), 143.5 (CH=C), 156.1 (NHCOO), 170.9 (NHCOCH2). Anal. Calc. for 
C106H210N16O28Si3 (2241.15): C, 56.81; H, 9.44; N, 10.00; Obt.: C, 56.59; H, 9.26; N, 9.74. 
Synthesis of dendrimer 12. Following the procedure described for 11, reaction of 5 (0.147 g, 0.109 
mmol) and 10 (0.150 g, 0.095 mmol) at 40ºC afforded 12 as yellowish oil (0.222 g, 80 %). NMR data 
(CDCl3): 
1H NMR: -0.11 (s, 9 H, SiMe), -0.07 (s, 24 H, SiMe), 0.47 (m, 10 H, CH2Si), 0.52 (m, 24 H, 
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CH2Si), 1.23 (m, 14 H, CH2CH2CH2), 1.41 (m, 80 H, SiCH2CH2CH2N and tBu), 1.73 (m, 16 H, 
OCH2CH2CH2N), 1.89 (m, 2 H, N-NCH2CH2), 2.54 (t, J = 7.3 Hz, 2 H, NCH2CH2N), 2.68 (t, J = 7.3 Hz, 
2 H, NCH2CH2N), 3.04 (m, 8 H, CH2NH), 3.16 (m, 16 H, CH2NH, CH2CO), 3.28 (m, 8 H, CH2NH), 3.45-
3.60 (m, 48 H, OCH2), 3.70 (s, 2 H, CspCH2N), 4.30 (t, J = 6.8 Hz, 2 H, CH2NN), 4.64 (br. s, 4 H, NH), 
5.05 (br. s, 4 H, NH), 7.48 (s, 1 H, CspH), 7.73 (br. s, 4 H, NH). 
13C NMR: -5.2 (SiMe), -4.9 (SiMe), -3.4 
(SiMe2), 12.4 (SiCH2CH2CH2N), 15.3 (SiCH2), 18.4, 18.7, 18.8, 19.0, 20.0, 21.2 (SiCH2 and SiCH2CH2), 
24.6 (SiCH2CH2CH2NH), 28.5 (CMe3), 29.7 (NHCH2CH2CH2O), 34.3 (N-NCH2CH2), 37.0 (CH2NH), 
38.4 (CH2NH), 43.8 (CH2NH), 46.3 (CspCH2N), 50.1 (CH2NN), 51.4 (NCH2CH2N), 52.7 (NCH2CH2N), 
58.7 (CH2CO), 69.3, 69.5, 70.2, 70.4, 70.5 (OCH2), 78.9 (CMe3), 122.7 (CH=C), 143.5 (CH=C), 156.1 
(NHCOO), 170.9 (NHCOCH2). Anal. Calc. for C140H284N18O32Si7 (2928.45): C, 57.42; H, 9.77; N, 8.61; 
Obt.: C, 57.31; H, 9.55; N, 8.44. 
Synthesis of dendrimer 13. Following the procedure described for 11, reaction of 6 (0.151 g, 0.056 
mmol) and 10 (0.080 g, 0.051 mmol) at 60ºC afforded 13 as yellowish oil (0.050 g, 23 %), after washing 
with hexane (5 ml) and purification through size-exclusion chromatography. NMR data (CDCl3): 
1H 
NMR: -0.07 (s, 15 H, SiMe), 0.47 (m, 6 H, CH2Si), 0.52 (m, 8 H, CH2Si), 1.23 (m, 6 H, CH2CH2CH2), 
1.41 (m, 122 H, CH2CH2CH2N and tBu), 1.73 (m, 16 H, OCH2CH2CH2N), 1.89 (m, 2 H, N-NCH2), 2.54 
(t, J = 7.3 Hz, 2 H, NCH2CH2N), 2.68 (t, J = 7.3 Hz, 2 H, NCH2CH2N), 3.04 (m, 16 H, CH2NH), 3.16 (m, 
16 H, CH2NH, CH2CO), 3.28 (m, 8 H, CH2NH), 3.45-3.60 (m, 48 H, OCH2), 3.70 (s, 2 H, CspCH2N), 4.30 
(t, J = 6.8 Hz, 2 H, CH2NN), 4.64 (br. s, 8 H, NH), 5.05 (br. s, 4 H, NH), 7.48 (s, 1 H, CspH), 7.73 (br. s, 4 
H, NH). 13C NMR: -5.1 (SiMe), -3.4 (SiMe2), 12.3 (SiCH2CH2CH2N), 18.3, 18.7, 18.8, 19.0, 19.7 (SiCH2 
and SiCH2CH2), 23.3 (SiCH2CH2CH2NH), 28.3 (CMe3), 29.5 (NHCH2CH2CH2O), 34.3 (N-NCH2CH2), 
36.8 (CH2NH), 38.3 (CH2NH), 43.6 (CH2NH), 46.3 (CspCH2N), 50.1 (CH2NN), 51.4 (NCH2CH2N), 52.7 
(NCH2CH2N), 58.7 (CH2CO), 69.1-70.4 (OCH2), 78.7 (CMe3), 129.4 (CH=C), 142.4 (CH=C), 155.8 
(NHCOO), 155.9 (NHCOO), 170.7 (NHCOCH2). Anal. Calc. for C208H432N22O40Si15 (4303.06): C, 58.06; 
H, 10.12; N, 7.16; Obt.: C, 57.81; H, 9.98; N, 7.02. 
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Synthesis of dendrimer 14. Compound 11 (0.150 g, 0.067 mmol) was mixed in CH2Cl2/H2O (5 mL 
each) and then excess HCl was added (8.04 mmol), and the suspension was stirred at ambient temperature 
for 3 h. Afterwards, volatiles were removed under vacuum, and the solid was washed with Et2O (2 x 15 
ml) and finally ultrafiltrated with a membrane of MWCO = 500 to give compound 14 as white powder 
(0.113 g, 91%). NMR data (DMSO-d6): 1H NMR: -0.05 (s, 3 H, SiMe (e)), -0.02 (s, 12 H, SiMe2 (i)), 0.55 
(m, 14 H, CH2Si (f, h, j)), 1.30 (m, 10 H, CH2CH2CH2 and SiCH2CH2CH2N (c, g, k)), 1.65-1.85 (m, 22 H, 
CH2CH2CH2N (b, h’, o’)), 2.73 (m, 2 H, NCH2CH2N (c’)), 2.80 (m, 2 H, NCH2CH2N (d’)), 3.05 (m, 2 H, 
NCH2CH2N (d’)), 3.15-3.40 (m, 20 H, CH2NH and CH2NH (l, n’, p’)), 3.50-3.90 (m, 58 H, CH2CO and 
OCH2 (b’, j’-m’)), 4.35 (m, 2 H, CH2NN (a)), 7.67 (m, 1 H, CspH (a’)), 8.14 (br. S, 30 H, NH3
+ (m, q’)), 
8.74 (br. s, 4 H, NH (f’)). 13C NMR: -5.4 (SiMe), -3.9 (SiMe2), 11.1 (SiCH2CH2CH2N), 13.6 (SiCH2), 
17.5, 18.7, 21.1, 21.8, 22.5 (SiCH2 and SiCH2CH2), 28.7, 29.2, (NCH2CH2CH2O), 35.0 (N-NCH2CH2), 
36.2 (CH2NH), 41.1 (CH2NH3), 46.3 (CspCH2N), 55.2 (NCH2CH2N), 59.3 (CH2CO), 68.8-69.5 (OCH2), 
122.7 (CH=C), 143.5 (CH=C), 165.8 (NHCOCH2). Anal. Calc. for C76H168Cl6N16O16Si3 (1859.22): C, 
49.10; H, 9.11; N, 12.05; Obt.: C, 48.77; H, 8.90; N, 11.91. 
Synthesis of dendrimer 15. Following procedure described for 14, reaction of 12 (0.150 g, 0.051 
mmol) and excess HCl in Et2O (12.24 mmol) afforded 15 as white powder (0.111 g, 90%). NMR data 
(DMSO-d6): 1H NMR: -0.07 (s, 33 H, SiMe and SiMe2), 0.55 (m, 30 H, CH2Si), 1.30 (m, 14 H, 
CH2CH2CH2 and SiCH2CH2CH2N), 1.50-1.87 (m, 26 H, CH2CH2CH2N), 2.70 and 2.80 (m, 8 H, 
CH2NH3
+), 3.05 (m, 4 H, NCH2CH2N), 3.30-3.67 (br. s, 66 H, CH2NH, CspCH2N, CH2CO and OCH2), 
4.24 (m, 2 H, CH2NN), CspH not observed, 8.14 (br. s, 36 H, NH3
+), CONH not observed. 13C NMR: -5.4 
(SiMe), -3.9 (SiMe2), 11.1 (SiCH2CH2CH2N), 13.6 (SiCH2), 17.5-22.1 (SiCH2 and SiCH2CH2), 28.7, 
29.2, (NCH2CH2CH2O), 35.4 (CH2), 41.1 (CH2NH3), 59.3 (CH2CO), 68.8-69.5 (OCH2), not observed 
(CH=C, CH=C and 165.8 NHCOCH2). Anal. Calc. for C100H228Cl8N18O16Si7 (2419.21): C, 49.65; H, 9.50; 
N, 10.42; Obt.: C, 49.33; H, 9.31; N, 10.24. 
Synthesis of dendrimer 16. Following procedure described for 14, reaction of 13 (0.075 g, 0.017 
mmol) and excess HCl in Et2O (8.16 mmol) afforded 16 as white powder (0.055 g, 89%). NMR data 
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(DMSO-d6): 1H NMR: -0.07 (s, 69 H, SiMe and SiMe2), 0.55 (m, 74 H, CH2Si), 1.30 (m, 30 H, 
CH2CH2CH2 and SiCH2CH2CH2N), 1.50-1.87 (m, 34 H, CH2CH2CH2N), 2.65-2.85 (br. s, 24 H, 
CH2NH3
+), 3.05 (m, 4 H, NCH2CH2N), 3.30-3.67 (br. s, 66 H, CH2NH, CspCH2N, CH2CO and OCH2), 
4.24 (m, 2 H, CH2NN), CspH not observed, 8.14 (br. s, 48 H, NH3
+), CONH not observed. The 13C NMR 
spectrum of this compound was not done due to the difficult to obtain a sufficient amount. Anal. Calc. for 
C148H348Cl12N22O16Si15 (3539.20): C, 50.23; H, 9.91; N, 8.71; Obt.: C, 50.01; H, 9.71; N, 8.62. 
Z potential and size measurements. The particle size and zeta-potential of the complexes were mea-
sured using a Zetasizer Nano ZS (Malvern Instruments Ltd., UK) at 25 ºC in a disposable Malvern plastic 
cuvette. The initial RNA concentration used was 250 nM. These samples were prepared and measured in 
10 mmol/L Na-phosphate buffer, pH 7.4, which was filtered through 22 nm filter paper prior to use.  
siRNA. All siRNA sequences were chosen from previously published results34,47,48 and had inhibited 
HIV replication in experiments using transiently transfected cells. They were purchased from Dharmacon. 
Inc. (Lafayette, CO). The sequence of the siRNA was siNEF sense: 
GUGCCUGGCUAGAAGCACAdTdT, antisense: UGUGCUUCUAGCCAGGCACdTdT. The siRNA 
siNEF labeled with the fluorochrome cyanine 3 (Cy3) on the 5′ end of the sense strand was used to detect 
entry of siRNA into cells. In siRNA functionality experiments, a siRNA of random sequence was used as 
a negative control to test for sequence-specific effects (siRandom). This siRNA was siCONTROL Non-
Targeting siRNA #2 and was designed and screened by Dharmacon to have no silencing effect on any 
human, mouse or rat genes. 
Primary cell cultures. Blood samples were obtained from healthy anonymous donors from the 
transfusion centers of Albacete and Madrid, following national guidelines. Peripheral blood mononuclear 
cells (PBMC) were isolated on a Ficoll-Hypaque density gradient (Rafer, Spain) following the current 
procedures of the Spanish HIV HGM BioBank.49 PBMC were activated with the mitogen 
phytohemagglutinin (PHA) (2μg/ml) and maintained in RPMI 1640 complete growth medium 
supplemented with 10% FBS and antibiotics along with interleukin-2 (20U/ml). 
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Dendriplex formation. Dendriplexes were formed by mixing equal volumes of dendrimer and siRNA 
dissolved in OPTIMEM® I free of serum or antibiotics at concentrations depending on the −/+ charge 
ratio and molar concentration desired.34,48 with an incubation time of 15 minutes. 
Heparin exclusion experiments. These experiments were used to test the strength of the binding 
between dendrimer and siRNA. They were carried out by mixing dendriplexes (−/+ ratio 4) of 14, (−/+ 
ratio 8) 15 or (−/+ ratio 2) 17 with varying concentrations of Heparin (0.1, 0.2, 0.3, and 0.6 U/μg siRNA). 
The mixture was run on a 2 % agarose gel, containing 1 μl/ml of GelRed (Biotium), for 2 h at 90 V. The 
gels were photographed and the bands were quantified using the program ImageJ (1.38×, NIH, USA). 
Cytotoxicity (MTT assay). PBMC were seeded in 96-well plates in OPTIMEM® I medium containing 
10 % FBS (1.5×105 cells in 190 μl/well) and submitted to 10 μl treatment of siRNA alone or complexed 
with 14, 15 or 17 at varying −/+ charge ratios. 20 h later, 20 μl MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium-bromide) substrate solution (5mg/ml) was added to the cells to measure 
mitochondrial activity. After 4 h, the supernatant was removed and the crystals formed were dissolved in 
200 μl DMSO, and absorbance was measured at 550 nm with a reference of 690 nm. All points were 
performed in triplicate. Dextrane (5M) and DMSO (15%) were used as positive and negative controls 
respectively. 
HIV inhibition. PBMC stimulated with PHA for up to 72 h were infected with HIV NL4-3 at 0.05 or 
0.01 MOI, respectively. The cells were washed twice with warm medium before being plated and treated 
with siRNA (250 nM) or dendriplexes at varying concentrations and −/+ charge ratios. The dendriplex 
treatment was applied to the infected cells within an hour of termination of the incubation with HIV. The 
dendriplex was formed in serum- and antibiotic-free OPTIMEM® I and incubated for 15 min at RT for the 
complex to form prior to its addition to the plated cells. Samples were collected every 24 h starting 24 h 
after treatment. They were then spun, and the supernatant was collected and assayed for viral 
concentration using the HIV protein p24 ELISA kit, following the manufacturer’s instructions. The 
dilution factors depended on the MOI  and the time point at which the sample was collected but ranged 
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Cationic ammonium Janus-type dendrimers have been synthesized via click chemistry coupling of 
carbosilane (generation 1 to 3) and PEG-based dendrons functionalized at the focal point with azide and 
alkyne moieties, respectively. These amphiphilic dendrimers have been studied as vectors for gene therapy 
against HIV in peripheral blood mononuclear cells (PBMC) and the results have been compared with a 
homocarbosilane dendrimer, observing the positive influence of the PEG unit. 
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